BECTON, DICKINSON AND COMPANY

BD announces the first pharma-sponsored combination product clinical trial using its BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics.

Waters Corporation and BD announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters in a $17.5 billion Reverse Morris Trust transaction.

Thermo Fisher Scientific is reportedly planning to divest portions of its diagnostics business valued at approximately $4 billion to offload lower-growth assets.

BD announced the initiation of the XTRACT Registry, a prospective multi-center study to assess real-world clinical performance of the Rotarex™ Atherectomy System in treating U.S. patients with peripheral artery disease.

• BD (Becton, Dickinson and Company) has globally launched the world's first cell analyzer combining spectral and real-time cell imaging technologies, enabling researchers to uncover previously invisible cellular insights with greater ease and throughput. • The new BD FACSDiscover A8 Cell Analyzer features SpectralFX Technology that allows scientists to analyze up to 50 characteristics of a single cell simultaneously, and CellView Image Technology that provides high-speed fluorescent and label-free imaging of cellular structures. • This groundbreaking instrument, alongside new software innovations including BD FACSChorus and FlowJo v11, represents a significant advancement in flow cytometry that will accelerate biomarker discovery and deepen understanding of cellular interactions across multiple research applications.

• BD (Becton, Dickinson and Company) has treated the first patient in its STANCE clinical trial, evaluating GalaFLEX LITE Scaffold for reducing capsular contracture recurrence during breast implant revision surgery. • Capsular contracture affects 10-20% of breast implant patients, with conventional revision techniques showing recurrence rates as high as 54%, highlighting the significant unmet medical need this trial addresses. • The multi-center study will enroll 250 patients across 40 sites, randomizing subjects 2:1 to receive either the bioabsorbable P4HB scaffold or standard care without supportive matrix.

• The global life science tools market is expected to grow from $179.44 billion in 2024 to $455.30 billion by 2033, driven by technological advancements in genomics, proteomics, and AI-powered analytics. • North America currently leads the market with a 39% share, while the Asia Pacific region is anticipated to experience the fastest growth rate due to increasing investments and expanding healthcare infrastructure. • Key growth drivers include rising demand for personalized medicine, increasing prevalence of chronic diseases, and substantial investments in R&D by pharmaceutical companies and government initiatives.

• The INTREPID trial demonstrated that targeted temperature management effectively reduced fever burden in ICU stroke patients compared to standard care. • Despite successful fever prevention, the study found no significant difference in functional recovery, as measured by the modified Rankin Scale (mRS) at 3 months. • Researchers suggest that the heterogeneous nature of cerebrovascular disease and variability in management options may contribute to the neutral outcome. • Experts emphasize the need for future research to identify specific patient subgroups that may benefit from fever prevention strategies after stroke.

BD has completed a 50-subject human clinical trial evaluating the performance of its BD Libertas Wearable Injector, a subcutaneous drug delivery system designed for biologics administration.